PMID- 25651948
OWN - NLM
STAT- MEDLINE
DCOM- 20190523
LR  - 20240210
IS  - 0070-217X (Print)
IS  - 0070-217X (Linking)
VI  - 405
DP  - 2017
TI  - The Use of Anti-CD40 mAb in Cancer.
PG  - 165-207
LID - 10.1007/82_2014_427 [doi]
AB  - Immunomodulatory monoclonal antibody (mAb) therapy is at the forefront of 
      developing cancer therapeutics with numerous targeted agents proving highly 
      effective in selective patients at stimulating protective host immunity, capable 
      of eradicating established tumours and leading to long-term disease-free states. 
      The cell surface marker CD40 is expressed on a range of immune cells and 
      transformed cells in malignant states whose signalling plays a critical role in 
      modulating adaptive immune responses. Anti-CD40 mAb therapy acts via multiple 
      mechanisms to stimulate anti-tumour immunity across a broad range of lymphoid and 
      solid malignancies. A wealth of preclinical research in this field has led to the 
      successful development of multiple anti-CD40 mAb agents that have shown promise 
      in early-phase clinical trials. Significant progress has been made to enhance the 
      engagement of antibodies with immune effectors through their interactions with 
      Fcgamma receptors (FcgammaRs) by the process of Fc engineering. As more is understood 
      about how to best optimise these agents, principally through the fine-tuning of 
      mAb structure and choice of synergistic partnerships, our ability to generate 
      robust, clinically beneficial anti-tumour activity will form the foundation for 
      the next generation of cancer therapeutics.
FAU - Remer, Marcus
AU  - Remer M
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton 
      General Hospital, Southampton, SO16 6YD, UK. m.e.remer@soton.ac.uk.
FAU - White, Ann
AU  - White A
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton 
      General Hospital, Southampton, SO16 6YD, UK.
FAU - Glennie, Martin
AU  - Glennie M
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton 
      General Hospital, Southampton, SO16 6YD, UK.
FAU - Al-Shamkhani, Aymen
AU  - Al-Shamkhani A
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton 
      General Hospital, Southampton, SO16 6YD, UK.
FAU - Johnson, Peter
AU  - Johnson P
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton 
      General Hospital, Southampton, SO16 6YD, UK.
LA  - eng
GR  - 10834/CRUK_/Cancer Research UK/United Kingdom
GR  - 13211/CRUK_/Cancer Research UK/United Kingdom
GR  - 19502/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Curr Top Microbiol Immunol
JT  - Current topics in microbiology and immunology
JID - 0110513
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (CD40 Antigens)
SB  - IM
MH  - Antibodies, Monoclonal/*immunology/*therapeutic use
MH  - CD40 Antigens/*antagonists & inhibitors/*immunology/metabolism
MH  - Humans
MH  - *Immunotherapy
MH  - Neoplasms/*drug therapy/*immunology/metabolism
MH  - Signal Transduction/drug effects
EDAT- 2015/02/06 06:00
MHDA- 2019/05/24 06:00
CRDT- 2015/02/06 06:00
PHST- 2015/02/06 06:00 [pubmed]
PHST- 2019/05/24 06:00 [medline]
PHST- 2015/02/06 06:00 [entrez]
AID - 10.1007/82_2014_427 [doi]
PST - ppublish
SO  - Curr Top Microbiol Immunol. 2017;405:165-207. doi: 10.1007/82_2014_427.